Matt Zeller, Novartis country president for Australia and New Zealand, said, “We welcome the PBS listing of KISQALI for node-positive patients at high risk of cancer recurrence. Importantly, this milestone provides the EBC community with more treatment choices, but we recognise there is still more work to be done."
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
